Phase 2 Depression and Anxiety Trial, Recruiting NCT06591091 Sponsor: University of Illinois at Chicago Condition: Depression and Anxiety
Back to Depression And Anxiety

Phase 2 Depression and Anxiety Trial, Recruiting

NCT06591091
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 60 years of age
  • People who have been diagnosed with major depressive disorder (a serious form of depression), whether it is their first episode or a recurring one
  • People whose depression symptoms are at a moderate level or above, based on a standard rating scale called the MADRS (confirm with trial site)
  • People who are currently looking to start treatment for their depression with antidepressant medication
  • People who score above 24 on a standard memory and thinking test called the MoCA, meaning their general thinking abilities are largely intact
  • People who are fluent in English or Spanish

Who may not be able to join:

  • People who have another major psychiatric diagnosis, except for simple phobias or anxiety-related conditions (such as generalised anxiety or panic disorder) that only appeared during the current depressive episode
  • People who have had a problem with alcohol or drug dependence or misuse in the past year
  • People who have a history of a developmental disorder, or who have a history of an IQ below 70
  • People who have had active thoughts of suicide in the past month, as assessed using a specific safety scale called the C-SSRS
  • People who are in the very early stages of grief, within the past month
  • People who currently have, or have previously had, psychosis (such as hallucinations or delusions)
  • People who have a primary neurological condition, including dementia, stroke, brain tumours, epilepsy, or similar conditions
  • People who have an unstable or serious physical health condition that needs urgent medical treatment
  • People who have any reason they cannot safely have an MRI scan (confirm with trial site)
  • People who have had electroconvulsive therapy (ECT), sometimes called shock therapy, within the past 6 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 312-413-4562

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
University of Illinois at Chicago
Registry
ClinicalTrials.gov
Start date
10 December 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Frequency, Intensity and Burden of Side Effects Rating Scale; Montgomery-Asberg Rating Scale for Depression; Quantitative Anisotropy; Fractional Anisotropy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov